Literature DB >> 15958049

Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin.

Richard H Steele1, Sandhya Limaye, Bruce Cleland, Josephine Chow, Michael G Suranyi.   

Abstract

The following case reports are of two patients who have developed hypersensitivity reactions to the red cell growth hormones, darbepoietin and erythropoietin. The subsequent skin testing and clinical course suggested that the cause of these reactions was due to the excipient polysorbate 80. This finding might have implications in the recent increase in the incidence of pure red cell aplasia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958049     DOI: 10.1111/j.1440-1797.2005.00389.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  15 in total

1.  Acute myositis in a patient with systemic sclerosis after the administration of darbepoetin alpha.

Authors:  C Palazzi; L D'Agostino; S D'Angelo; A Petricca; I Olivieri
Journal:  Rheumatol Int       Date:  2007-08-03       Impact factor: 2.631

2.  The human papillomavirus vaccine and risk of anaphylaxis.

Authors:  Neal A Halsey
Journal:  CMAJ       Date:  2008-09-01       Impact factor: 8.262

Review 3.  Hidden Causes of Anaphylaxis.

Authors:  Vivian C Nanagas; James L Baldwin; Keerthi R Karamched
Journal:  Curr Allergy Asthma Rep       Date:  2017-07       Impact factor: 4.806

4.  Anaphylaxis following quadrivalent human papillomavirus vaccination.

Authors:  Julia M L Brotherton; Mike S Gold; Andrew S Kemp; Peter B McIntyre; Margaret A Burgess; Sue Campbell-Lloyd
Journal:  CMAJ       Date:  2008-09-01       Impact factor: 8.262

5.  Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies.

Authors:  R Matthew Fesinmeyer; Sabine Hogan; Atul Saluja; Stephen R Brych; Eva Kras; Linda O Narhi; David N Brems; Yatin R Gokarn
Journal:  Pharm Res       Date:  2008-12-23       Impact factor: 4.200

6.  Omalizumab: Practical considerations regarding the risk of anaphylaxis.

Authors:  Harold L Kim; Richard Leigh; Allan Becker
Journal:  Allergy Asthma Clin Immunol       Date:  2010-12-03       Impact factor: 3.406

Review 7.  Challenges in development of nanoparticle-based therapeutics.

Authors:  Neil Desai
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 8.  Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions.

Authors:  Maria Luisa Caballero; Matthew S Krantz; Santiago Quirce; Elizabeth J Phillips; Cosby A Stone
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-15

Review 9.  Safety of Polysorbate 80 in the Oncology Setting.

Authors:  Lee S Schwartzberg; Rudolph M Navari
Journal:  Adv Ther       Date:  2018-05-23       Impact factor: 3.845

Review 10.  Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors:  Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal:  Exp Ther Med       Date:  2021-07-03       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.